Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
Ann Thorac Surg ; 93(2): 457-63, 2012 Feb.
Article in English | MEDLINE | ID: mdl-22206960

ABSTRACT

BACKGROUND: Congenital bicuspid aortic valves (BAVs) result from fusion of 2 valve cusps, resulting in left-noncoronary (L-N), right-left (R-L), and right-noncoronary (R-N) morphologic presentations. BAVs predispose to ascending thoracic aortic aneurysms (ATAAs). This study hypothesized that ATAAs with each BAV morphologic group possess unique signatures of matrix metalloproteinases (MMPs) and endogenous tissue inhibitors of metalloproteinases (TIMPs). METHODS: Ascending thoracic aortic aneurysm tissue from 46 patients with BAVs was examined for MMP/TIMP abundance, and global MMP activity was compared with normal aortic specimens (n=15). Proteolytic balance was calculated as the ratio of MMP abundance to a composite TIMP score. Results were stratified by valve morphologic group (L-N [n=6], R-L [n=31], and R-N [n=9]). RESULTS: The BAV specimens (p<0.05 versus normal aorta, 100%) displayed elevated global MMP activity (273%±63%), MMP-9 (263%±47%), and decreased MMP-7 (56%±10%), MMP-8 (58%±11%), TIMP-1 (63%±7%), and TIMP-4 (38%±3%). The R-L group showed increased global MMP activity (286%±89%) and MMP-9 (267%±55%) with reduced MMP-7 (45%±7%), MMP-8 (68%±15%), TIMP-1 (58%±7%), and TIMP-4 (35%±3%). The L-N group showed elevated global MMP activity (284%±71%) and decreased MMP-8 (37%±17%) and TIMP-4 (48%±14) activity. In the R-N group, MMP-7 (46%±13%) and MMP-8 (36%±17%) and TIMP-1 (59%±10%) and TIMP-4 (42%±5%) were decreased. The R-L group demonstrated an increased proteolytic balance for MMP-1, MMP-9, and MMP-12 relative to L-N and R-N. CONCLUSIONS: Each BAV morphologic group possesses a unique signature of MMPs and TIMPs. MMP/TIMP score ratios suggest that the R-L group may be more aggressive, justifying earlier surgical intervention.


Subject(s)
Aorta/abnormalities , Aortic Valve/abnormalities , Matrix Metalloproteinases/analysis , Tissue Inhibitor of Metalloproteinases/analysis , Adult , Aged , Aorta/enzymology , Aorta/pathology , Aorta/surgery , Aortic Aneurysm, Thoracic/epidemiology , Aortic Aneurysm, Thoracic/etiology , Aortic Valve/enzymology , Aortic Valve/pathology , Aortic Valve/surgery , Blood Vessel Prosthesis Implantation , Dilatation, Pathologic/enzymology , Disease Susceptibility , Elastic Tissue/pathology , Extracellular Matrix Proteins/analysis , Female , Humans , Male , Middle Aged
2.
Am J Physiol Heart Circ Physiol ; 299(1): H114-24, 2010 Jul.
Article in English | MEDLINE | ID: mdl-20418476

ABSTRACT

Thoracic aortic aneurysms (TAAs) develop as a result of dysregulated extracellular matrix remodeling mediated by several matrix metalloproteinases (MMPs). Membrane type-1 MMP (MT1-MMP) is the prototypical member of a unique family of membrane-bound MMPs, possessing multiple substrates and functions. The present study tested the hypothesis that MT1-MMP expression, abundance, and activity would be elevated during TAA development and that this protease is produced primarily by mesenchymal cells within the thoracic aorta. Descending thoracic aortas were harvested from C57BL/6J mice at multiple time points (2, 4, 8, and 16 wk, n = 15 each) post-TAA induction (0.5M CaCl(2), 15 min) and compared with reference controls (n = 15). The expression and abundance of MT1-MMP, MMP-2, and tissue inhibitor of metalloproteinase (TIMP)-2 were assessed by quantitative PCR and immunoblot analysis. MT1-MMP activity was determined by fluorescent peptide assay. MT1-MMP was localized within the aortic wall by immunohistochemistry. MT1-MMP abundance and localization in live animals (8 wk post-TAA induction vs. control) was determined by micro-ultrasound imaging with an MT1-MMP-targeted microbubble contrast agent. Aortic diameter was increased 172 +/- 7% at 16 wk post-TAA induction (P < 0.05). MT1-MMP and MMP-2 mRNA levels were elevated at 2 wk post-TAA induction (P < 0.05). MT1-MMP protein abundance increased progressively to a maximum of 178 +/- 26% at 16 wk post-TAA induction, whereas MMP-2 and TIMP-2 peaked at 2 wk post-TAA induction (526 +/- 93% and 376 +/- 48%, respectively, P < 0.05). MT1-MMP colocalized with fibroblasts, and MT1-MMP-targeted contrast binding was elevated in 8-wk TAA-induced mice versus control mice (217 +/- 53% vs. 81 +/- 8%, P < 0.05). In conclusion, these novel results suggest that MT1-MMP plays a dynamic multifunctional role in TAA development and, therefore, may provide a significant target for therapeutic strategies.


Subject(s)
Aorta, Thoracic/enzymology , Aortic Aneurysm, Thoracic/enzymology , Matrix Metalloproteinase 14/metabolism , Animals , Aorta, Thoracic/diagnostic imaging , Aortic Aneurysm, Thoracic/chemically induced , Aortic Aneurysm, Thoracic/diagnostic imaging , Aortic Aneurysm, Thoracic/genetics , Blotting, Western , Calcium Chloride , Contrast Media , Dilatation, Pathologic , Disease Models, Animal , Female , Fibroblasts/enzymology , Gene Expression Regulation, Enzymologic , Immunohistochemistry , Male , Matrix Metalloproteinase 14/genetics , Matrix Metalloproteinase 2/metabolism , Mice , Mice, Inbred C57BL , Microbubbles , RNA, Messenger/metabolism , Reverse Transcriptase Polymerase Chain Reaction , Time Factors , Tissue Inhibitor of Metalloproteinase-2/metabolism , Ultrasonography , Up-Regulation
3.
Circulation ; 108(5): 598-604, 2003 Aug 05.
Article in English | MEDLINE | ID: mdl-12874189

ABSTRACT

BACKGROUND: The functional significance of cross-regulation between the renin-angiotensin system (RAS) and tumor necrosis factor (TNF) has been established in nonmyocyte cell types; however, the degree and functional significance of the interaction between RAS and TNF has not been characterized in the heart. METHODS AND RESULTS: We examined the expression of components of the RAS in a line of transgenic mice (MHCsTNF) with cardiac restricted overexpression of TNF. When examined at 4, 8, and 12 weeks of age, the MHCsTNF mice had increased activation of myocardial RAS, as shown by an increase in ACE mRNA level and ACE activity and increased angiotensin II peptide levels. Furthermore, myocardial angiotensin receptor mRNA and protein levels were reduced in the MHCsTNF mice, consistent with homologous desensitization of the receptors. However, expression of renin and angiotensinogen was not increased in MHCsTNF mice compared with littermate controls. To determine the functional significance of RAS activation in the MHCsTNF mice, we treated the mice with an angiotensin type I receptor antagonist, losartan (30 mg/kg), or diluent from 4 to 8 weeks of age. Analysis of cardiac structure with MRI showed that treatment with losartan normalized left ventricular mass and wall thickness. Furthermore, treatment with losartan reduced myocardial collagen content and reduced the incidence of myocyte apoptosis. CONCLUSIONS: Taken together, these results show that there are functionally significant interactions between RAS and TNF in the heart and that these interactions play an important role in the development and progression of left ventricular remodeling.


Subject(s)
Cardiomegaly/genetics , Myocardium/metabolism , Renin-Angiotensin System/physiology , Tumor Necrosis Factor-alpha/biosynthesis , Tumor Necrosis Factor-alpha/genetics , Age Factors , Angiotensin I/metabolism , Angiotensin II/metabolism , Angiotensin Receptor Antagonists , Angiotensinogen/biosynthesis , Angiotensinogen/genetics , Animals , Body Weight/drug effects , Body Weight/genetics , Cardiomegaly/drug therapy , Cardiomegaly/metabolism , Collagen/metabolism , Hemodynamics/drug effects , Losartan/pharmacology , Mice , Mice, Transgenic , Organ Size/drug effects , Organ Size/genetics , Organ Specificity , Peptidyl-Dipeptidase A/genetics , Peptidyl-Dipeptidase A/metabolism , RNA, Messenger/metabolism , Receptor, Angiotensin, Type 1 , Receptor, Angiotensin, Type 2 , Receptors, Angiotensin/genetics , Receptors, Angiotensin/metabolism , Renin/biosynthesis , Renin/genetics , Renin-Angiotensin System/drug effects , Renin-Angiotensin System/genetics , Ventricular Remodeling/drug effects , Ventricular Remodeling/physiology
4.
J Thorac Cardiovasc Surg ; 125(3): 602-10, 2003 Mar.
Article in English | MEDLINE | ID: mdl-12658202

ABSTRACT

BACKGROUND: Global and regional shape changes that occur within the left ventricular wall after myocardial infarction have been termed infarct expansion. A potential mechanism for this postinfarction remodeling is activation of the matrix metalloproteinases. Accordingly, the present study examined the effects of matrix metalloproteinase inhibition on left ventricular global geometry after myocardial infarction in pigs. METHODS: Myocardial infarction was created in pigs by means of occlusion of the first and second obtuse marginal branches of the circumflex coronary artery, resulting in a uniform left ventricular free wall infarct size of 21% +/- 2%. At 5 days after infarction, the pigs were randomized to undergo broad-spectrum matrix metalloproteinase inhibition (n = 9; PD166793, 20 mg. kg(-1). d(-1) by mouth) or myocardial infarction alone (n = 8). Ten pigs served as noninfarction control animals. Left ventricular end-diastolic area, determined by means of echocardiography, was measured 8 weeks after infarction. RESULTS: Left ventricular end-diastolic area increased in both the myocardial infarction plus broad-spectrum matrix metalloproteinase inhibition and myocardial infarction only groups compared to reference control animals (3.7 +/- 0.2 cm(2)), but was reduced with broad-spectrum matrix metalloproteinase inhibition compared to myocardial infarction alone (4.5 +/- 0.2 vs 4.9 +/- 0.2 cm(2), respectively; P <.05). Regional radial stress within the infarct region increased in both infarction groups when compared to values obtained from reference control animals (599 +/- 152 g/cm(2)), but was attenuated in the myocardial infarction plus broad-spectrum matrix metalloproteinase inhibition group compared to the myocardial infarction alone group (663 +/- 108 vs 1242 +/- 251 g/cm(2), respectively; P <.05). Similarly, regional myocardial stiffness increased in both the myocardial infarction plus broad-spectrum matrix metalloproteinase inhibition and the myocardial infarction only groups compared with that observed in reference control animals (14 +/- 1 rkm, P <.05) but was lower with broad-spectrum matrix metalloproteinase inhibition than with myocardial infarction alone (42 +/- 6 vs 68 +/- 10 rkm, respectively; P <.05). CONCLUSIONS: Matrix metalloproteinase inhibition reduced postinfarction left ventricular dilation, reduced regional myocardial wall stress, and modified myocardial material properties. These unique findings suggest that increased myocardial matrix metalloproteinase activation after infarction contributes directly to the left ventricular remodeling process.


Subject(s)
Disease Models, Animal , Hydroxamic Acids/therapeutic use , Matrix Metalloproteinase Inhibitors , Matrix Metalloproteinases/physiology , Myocardial Infarction/drug therapy , Myocardial Infarction/enzymology , Oligopeptides/therapeutic use , Tissue Inhibitor of Metalloproteinases/therapeutic use , Ventricular Dysfunction, Left/etiology , Ventricular Remodeling/drug effects , Analysis of Variance , Animals , Disease Progression , Drug Evaluation, Preclinical , Echocardiography, Transesophageal , Hemodynamics/drug effects , Hydroxamic Acids/pharmacology , Myocardial Infarction/complications , Myocardial Infarction/diagnosis , Oligopeptides/pharmacology , Random Allocation , Stroke Volume/drug effects , Swine , Time Factors , Tissue Inhibitor of Metalloproteinases/pharmacology , Ventricular Dysfunction, Left/prevention & control , Ventricular Pressure/drug effects
5.
Circulation ; 107(4): 618-25, 2003 Feb 04.
Article in English | MEDLINE | ID: mdl-12566376

ABSTRACT

BACKGROUND: A potential mechanism for left ventricular (LV) remodeling after myocardial infarction (MI) is activation of the matrix metalloproteinases (MMPs). This study examined the effects of MMP inhibition (MMPi) on regional LV geometry and MMP levels after MI. METHODS AND RESULTS: In pigs instrumented with radiopaque markers to measure regional myocardial geometry, MI was created by ligating the obtuse marginals of the circumflex artery. In the first study, pigs were randomized to MMPi (n=7; PD166793, 20 mg x kg(-1) x d(-1)) or MI only (n=7) at 5 days after MI, and measurements were performed at 2 weeks. Regional MI areas were equivalent at randomization and were increased in the MI-only group at 2 weeks after MI compared with the MMPi group. In the second study, pigs randomized to MMPi (n=9) or MI only (n=8) were serially followed up for 8 weeks. At 8 weeks after MI, LV end-diastolic dimension was lower with MMPi than in the MI-only group (4.7+/-0.1 versus 5.1+/-0.1 cm, P<0.05). Regional MI area was reduced with MMPi at 8 weeks after MI (1.3+/-0.1 versus 1.7+/-0.1 cm2, P<0.05). MMPi reduced ex vivo MMP proteolytic activity. In the MI region, membrane-type MMP levels were normalized and levels of the endogenous tissue inhibitor of MMPs (TIMP-1) were increased compared with normal levels with MMPi. These effects were not observed in the MI-only group. CONCLUSIONS: MMPi attenuated the degree of post-MI LV dilation and expansion of the infarct during the late phase of MI healing. In addition, exogenous MMPi caused region-specific modulation of certain MMP and TIMP species.


Subject(s)
Enzyme Inhibitors/pharmacology , Hydroxamic Acids/pharmacology , Matrix Metalloproteinase Inhibitors , Myocardial Infarction/enzymology , Myocardium/metabolism , Oligopeptides/pharmacology , Animals , Chronic Disease , Dilatation, Pathologic/prevention & control , Disease Models, Animal , Disease Progression , Enzyme Activation/drug effects , Hemodynamics/drug effects , Matrix Metalloproteinases/metabolism , Myocardial Infarction/pathology , Myocardium/pathology , Swine , Tissue Inhibitor of Metalloproteinase-1/metabolism , Tissue Inhibitor of Metalloproteinases/metabolism , Ventricular Function, Left/drug effects , Ventricular Remodeling/drug effects , Tissue Inhibitor of Metalloproteinase-4
SELECTION OF CITATIONS
SEARCH DETAIL
...